• Mantle Cell Lymphoma
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion
  • Waldenstriim's Macroglobulinemia
  • Marginal Zone Lymphoma
  • Chronic Graft versus Host Disease

Dosage and Administration

  • Mantle Cell Lymphoma and Marginal Zone Lymphoma
  • The recommended dose of lbrutinib for MCL and MZL is 560 mg (four 140 mg tablets) orally once daily.
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenstriim's Macroglobulinemia
  • The recommended dose of lbrutinib for CLL/SLL and WM is 420 mg orally once daily.
  • The recommended dose of lbrutinib for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg orally once daily.
  • Chronic Graft versus Host Disease
  • The recommended dose of lbrutinib for cGVHD is 420 mg orally once daily.